Effect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis: a randomized placebo-controlled double-blind study.

SUMMARY; A randomized placebo-controlled trial was conducted to examine the effect of daily oral 1 mg minodronate on vertebral fractures in 704 postmenopausal women with established osteoporosis for 24 months. Minodronate treatment reduced vertebral fractures by 59% without serious adverse events. Minodronate is a safe and effective bisphosphonate for osteoporosis treatment.
Minodronate increases bone mineral density (BMD) in postmenopausal osteoporotic patients. However, its efficacy in reducing osteoporotic fractures has not been tested.
To examine anti-fracture efficacy and safety of daily oral minodronate in postmenopausal women with established osteoporosis, a randomized, double-blind, placebo-controlled trial was conducted in 704 postmenopausal women (55 to 80 years) with one to five vertebral fractures and low BMD. Subjects were randomly assigned to receive daily oral 1 mg minodronate (n = 359) or placebo (n = 345) for 24 months, with daily supplements of 600 mg calcium and 200 IU vitamin D(3).
Daily 1 mg minodronate for 24 months reduced the risk of vertebral fractures by 59% (95% CI, 36.6-73.3%). Furthermore, when fractures during the first 6 months were eliminated, the risk of vertebral fractures from 6 to 24 months was reduced by 74% in minodronate-treated group. Minodronate treatment also reduced height loss. Bone turnover markers were suppressed by about 50% after 6 months of minodronate treatment and remained suppressed thereafter. The overall safety profile including gastrointestinal safety was similar between the two groups.
Daily oral minodronate is safe, well-tolerated, and is effective in reducing vertebral fracture risk in postmenopausal women with established osteoporosis.
AuthorsT Matsumoto, H Hagino, M Shiraki, M Fukunaga, T Nakano, K Takaoka, H Morii, Y Ohashi, T Nakamura
JournalOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (Osteoporos Int) Vol. 20 Issue 8 Pg. 1429-37 (Aug 2009) ISSN: 1433-2965 [Electronic] England
PMID19101754 (Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial)
Chemical References
  • Biomarkers
  • Bone Density Conservation Agents
  • Diphosphonates
  • Imidazoles
  • YM 529
  • Administration, Oral
  • Aged
  • Aged, 80 and over
  • Biomarkers (metabolism)
  • Body Height (drug effects)
  • Bone Density Conservation Agents (administration & dosage, adverse effects, therapeutic use)
  • Bone Remodeling (drug effects)
  • Diphosphonates (administration & dosage, adverse effects, therapeutic use)
  • Double-Blind Method
  • Drug Administration Schedule
  • Female
  • Fractures, Bone (etiology, prevention & control)
  • Humans
  • Imidazoles (administration & dosage, adverse effects, therapeutic use)
  • Middle Aged
  • Osteoporosis, Postmenopausal (complications, drug therapy, physiopathology)
  • Spinal Fractures (etiology, prevention & control)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: